Yes, targeting these pathways has been a key strategy in cancer therapy. Targeted therapies and inhibitors that specifically block components of these pathways can effectively halt cancer progression. For example, mTOR inhibitors like rapamycin are used in treating cancers with hyperactive PI3K/AKT/mTOR signaling.
